Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: A study at a regional south african hospital

AIDS

Volumn 24, Issue 2, 2010, Pages 283-289

  Bera, Ebrahim ^a,b   McCausland, Katrin ^a   Nonkwelo, Roxaan ^a   Mgudlwa, Batembu ^a   Chacko, Saji ^a   Majeke, Busiwe ^a  

^a WALTER SISULU UNIVERSITY   (South Africa)

^b Frere Hospital   (South Africa)

Author keywords

Antiretroviral therapy; Birth defects; Efavirenz; HIV; Pregnancy; South Africa

Indexed keywords

EFAVIRENZ; NEVIRAPINE;

ADULT; ARACHNOID CYST; ARTHROGRYPOSIS; ARTICLE; BIRTH DEFECT; CLEFT LIP; CLEFT PALATE; CLUBFOOT; CONCEPTION; CONGENITAL NEVUS; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGUS ATRESIA; FACE ASYMMETRY; FACE MALFORMATION; FEMALE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JOINT CONTRACTURE; LIVE BIRTH; LONG TERM CARE; LUNG HYPOPLASIA; MAJOR CLINICAL STUDY; POLYDACTYLY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SACRUM AGENESIS; SECOND TRIMESTER PREGNANCY; SOUTH AFRICA; SYNDACTYLY; THERAPY EFFECT; THIRD TRIMESTER PREGNANCY; TOOTH MALFORMATION; TRACHEOESOPHAGEAL FISTULA; TRISOMY 18; UMBILICAL HERNIA;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; FEMALE; HIV INFECTIONS; HUMANS; INFANT; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTERS; PRENATAL EXPOSURE DELAYED EFFECTS; PREVALENCE; PROSPECTIVE STUDIES; SOUTH AFRICA; ULTRASONOGRAPHY, PRENATAL;

EID: 74249094734     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328333af32     Document Type: Article

References (29)

1. Lewis-Hall FC. Important Change in SUSTIVA (efavirenz) Package Insert-Change from Category C to D. Bristol-Myers Squibb Company 2005. http://www.fda.gov. (Accessed 19 April 2008).
2. Bristol-Myers Squibb Company. Efavirenz drug label; 2008.
3. De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002; 162:355.
4. Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16:299-300.
5. Saitoh A, Hull AD, Franklin P, Spector SA. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 2005; 25:555-556.
6. Urban MF, Chersich MF. Dandy-Walker variant in an infant prenatally exposed to antiretroviral medication. S Afr Med J 2007; 97:947-948.
7. Public Health Service Task Force. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy; 29 April 2009. http://AIDSinfo.nih.gov. (Accessed 6 July 2009)
8. Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AJ, Andrews EB. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000; 182:159-163.
9. Antiretroviral Pregnancy Registry Steering Committee. Antire-troviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2009. Wilmington, NC: Registry Coordinating Center 2008. www.APRegistry.com. (Accessed 31 July 2009).
10. Patel D, Thorne C, Fiore S, Newell ML. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr 2005; 40:116-118.
11. Watts HD, Li D, Handelsman E, Tilson H, Paul M, Foca M, et al. Assessment of birth defects according to maternal therapy among infants in the women and infants transmission study. J Acquir Immune Defic Syndr 2007; 44:299-305.
12. Bussmann H, Wester WC, Wester CN, Lekoko B, Okezie O, Thomas AM, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J Acquir Immune Defic Syndr 2007; 45:269-273.
13. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Too-key PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS 2009; 23:519-524.
14. Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, et al. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 2008; 22:2117-2125.
15. National Department of Health. National HIV and Syphilis Antenatal Seroprevalence Survey in South Africa 2007. Pretoria, South Africa: Directorate: Health Systems Research, Research Coordination and Epidemiology, Department of Health 2008 http://www.doh.gov.za. (Accessed 20 April 2008)
16. De Lazzari E, Leon A, Arniaz JA, Martinez E, Knobel H, Negredo E, et al. Risk of hepatotoxicity in virologically suppressed HIV patients switching to nevirapine according to gender and CD4 count. 46th ICAAC, San Francisco, CA. September 27-30, 2006. Abstract H-1064.
17. Watts HD, Covington DL, Beckerman K, Garcia P, Scheuerle A, Dominguez K, et al. Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol 2004; 191:985-992.
18. Royal College of Obstetricians and Gynaecologists. The management of early pregnancy loss. Guideline No. 25. London: RCOG; 2006.
19. Venter PA, Christianson AL, Gericke GS, Hutamo CM, Makhura MP. Congenital anomalies in rural black South African neo-nates: a silent epidemic? S Afr Med J 1995; 85:15-20.
20. Human Genetics Policy Guidelines for the Management and Prevention of Genetic Disorders, Birth Defects and Disabilities. Pretoria, South Africa: Sub-Directorate, Human Genetics, National Department of Health 2008 www.doh.gov.za. (Accessed 29 December 2008) National Department of Health. National Antiretroviral Treatment Guidelines. 1st ed. Pretoria, South Africa: Jacana 2004
21. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Geneva, Switzerland: WHO; 2006.
22. Back D, Gibbons S, Khoo S. Pharmacokinetic Drug Interactions with Nevirapine. J Acquir Immune Defic Syndr 2003; 34 (Suppl 1):S08-S14.
23. van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JMA, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavir-enz-based first-line HAART. AIDS 2005; 19:463-471.
24. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35:538-539.
25. Tariq Sadiq S, Fredericks S, Khoo SH, Rice P, Holt DW. Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of nonnucleoside reverse tran-scriptase inhibitor-associated resistance. AIDS 2005; 19:1716-1717.
26. Rankin J, Pattenden S, Abramsky L, Boyd P, Jordan H, Stone D, et al. Prevalence of congenital anomalies in five British regions, 1991-1999. Arch Dis Child Fetal Neonatol Ed 2005; 90:F374-F379.
27. Robertson H-L, Steyn NP, Venter PA, Christianson AL. Neural tube defects and folic acid: a South African perspective. S Afr Med J 1997; 87:928-931.
28. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-1612.
29. Rossouw T. Quantifying antiretroviral risk in pregnancy. S Afr Med J 2007; 97:1014-1016.